Method for induction of apoptotic cell death in malignant cells, through reduction of the rb to apoptosis inducing proteins ratio
CA 2283090 A1 · Owner: Hepavec Aktiengesellschaft Fur Gentherapie · Inventors: Strauss, Michael; Sandig, Volker; Bartek, Jiri
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to use of a vector containing genetic material for the preparation of a composition for the treatment of malignant disease said vector, upon administration in a subject suffering from malignant disease, inducing apoptosis in malignant cells by reducing the ratio of the level of pRb protein to the level of an apoptosis-inducing protein in malignant cells, by reducing the level of pRb and increasing the level of the apoptosis-inducing protein, after having first achieved growth arrest of said malignant cells by inducing herein an inhibition of phosphorylation of the pRb protein. The invention further relates to specific vectors for efficient transfer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 20, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 20, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 20, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.